Andrew Berens, an analyst from Leerink Partners, maintained the Hold rating on Arvinas Holding Company. The associated price target remains the same with $9.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Berens has given his Hold rating due to a combination of factors surrounding Arvinas Holding Company’s recent developments and strategic decisions. The company’s collaboration with Pfizer over the drug vepdegestrant has encountered challenges, as the market opportunity has been narrowed to a specific patient population, making it less appealing for Pfizer. This has led to ongoing negotiations about the future of the partnership, with potential outcomes including either company taking control of the asset.
Additionally, while Arvinas is progressing with its pipeline, including early-stage trials for other assets, the lack of a clear commercialization partner for vepdegestrant and the absence of a dedicated sales force for its launch contribute to the uncertainty. These factors, combined with the need for further clarity on development and commercialization strategies, underpin Berens’s decision to maintain a Hold rating on the stock.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $6.50 price target.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year.